Dual Antiplatelet Therapy in Coronary Artery Disease: Comparison Between ACC/AHA 2016 and ESC 2017 Guidelines
Dual antiplatelet therapy (DAPT) is integral to the management of coronary artery disease (CAD) but there remains uncertainty as to the optimal approach for balancing an individual’s risk of atherothrombotic events versus their risk of bleeding complications. A myriad of clinical trials have investi...
Saved in:
| Main Author: | Christopher N Floyd |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Radcliffe Medical Media
2020-02-01
|
| Series: | European Cardiology Review |
| Online Access: | https://www.ecrjournal.com/articleindex/ecr.2019.09 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Validation of ACC/AHA and ESC Sudden Cardiac Death Risk Guidelines in Diverse Hypertrophic Cardiomyopathy Cohort: Stratification HCM Study
by: Murillo Oliveira Antunes, et al.
Published: (2024-12-01) -
Early-stage hypertension defined by the 2017 ACC/AHA blood pressure guideline carries excessive cardiovascular risk in axial spondyloarthritis patients
by: Lin-Hong Shi, et al.
Published: (2024-11-01) -
Impact of the 2017 ACC/AHA guideline on the prevalence of elevated blood pressure and hypertension: a cross-sectional analysis of 10 799 individuals
by: Ahmed Alaskar, et al.
Published: (2020-12-01) -
Cardiovascular events according to blood pressure thresholds recommended by ACC/AHA
by: Gowsini Joseph, et al.
Published: (2024-12-01) -
Bridging the gaps: Insights from the 2024 ESC guidelines on peripheral arterial and aortic diseases
by: Fabio Massimo Oddi, et al.
Published: (2024-12-01)